Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 75 clinical trials
A Randomized Phase IIB Multicenter Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study

  • 27 Mar, 2021
  • 1 location
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical

  • 22 Jan, 2021
  • 1 location
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in newly-diagnosed T-NHL.

measurable disease
peripheral t-cell lymphoma
  • 21 Jan, 2021
  • 1 location
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T

  • 05 Feb, 2021
  • 1 location
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-,, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL

t-cell lymphoma
measurable disease
large cell lymphoma
anaplastic large cell lymphoma
angioimmunoblastic t-cell lymphoma
  • 28 Mar, 2021
  • 28 locations
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

peripheral T-cell lymphoma or transformed mycosis fungoides, whose tumor expresses the surface marker CD30, and who have relapsed after an earlier treatment or have refractory disease will be enrolled into

mycosis fungoides
fungal infection
t-cell lymphoma
  • 30 Apr, 2021
  • 82 locations
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

skin lesion
mycosis fungoides
anaplastic large cell lymphoma
large cell lymphoma
  • 26 Jan, 2021
  • 36 locations
Study of Tinostamustine First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

mycosis fungoides
refractory peripheral t-cell lymphoma
anaplastic large cell lymphoma
refractory hodgkin lymphoma
  • 27 Jan, 2021
  • 25 locations
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

extranodal nk/t-cell lymphoma, nasal type
chronic lymphocytic leukemia
cluster of differentiation
anaplastic large cell lymphoma
  • 13 Apr, 2021
  • 2 locations
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

targeted therapy
cancer chemotherapy
stem cell transplantation
positron emission tomography
  • 10 May, 2021
  • 11 locations